{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Tempest Therapeutics, Inc.
Is Tempest Therapeutics, Inc. technically bullish or bearish?
As of June 11, 2025, Tempest Therapeutics, Inc. shows a mildly bearish trend due to bearish daily moving averages and weekly indicators, despite some mixed signals from the MACD and RSI.
Who are in the management team of Tempest Therapeutics, Inc.?
As of March 2022, the management team of Tempest Therapeutics, Inc. includes Dr. Carol Gallagher as the Independent Chairman and Dr. Julia Owens as President and CEO, along with several Independent Directors: Mr. Habib Dable, Dr. Mary Hedley, Mr. James Hindman, Dr. John Howe, and Dr. Geoffrey Nichol.
What does Tempest Therapeutics, Inc. do?
Tempest Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing treatments for orphan endocrine diseases. It has a market cap of $28 million and reported a net profit loss of $11 million as of March 2025.
How big is Tempest Therapeutics, Inc.?
As of Jun 18, Tempest Therapeutics, Inc. has a market capitalization of 28.00 million and reported net sales of 0.00 million with a net profit of -44.80 million over the last four quarters. As of Dec 24, the company's shareholder's funds were 19.13 million, and total assets amounted to 44.02 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
